The Gap Junction Modifier, GAP-134 [(2S,4R)-1-(2-Aminoacetyl)-4-benzamido-pyrrolidine-2-carboxylic Acid], Improves Conduction and Reduces Atrial Fibrillation/Flutter in the Canine Sterile Pericarditis Model

  title={The Gap Junction Modifier, GAP-134 [(2S,4R)-1-(2-Aminoacetyl)-4-benzamido-pyrrolidine-2-carboxylic Acid], Improves Conduction and Reduces Atrial Fibrillation/Flutter in the Canine Sterile Pericarditis Model},
  author={Eric I. Rossman and Kun Liu and Gwen A. Morgan and Robert E. Swillo and Julie A. Krueger and Stephen J. Gardell and John A. Butera and Matthew Gruver and J. D. Kantrowitz and Hal S. Feldman and J{\o}rgen S{\o}berg Petersen and Ketil Haugan and James K. Hennan},
  journal={Journal of Pharmacology and Experimental Therapeutics},
  pages={1127 - 1133}
Gap junction uncoupling can alter conduction pathways and promote cardiac re-entry mechanisms that potentiate many supraventricular arrhythmias, such as atrial fibrillation (AF) and atrial flutter (AFL). Our objective was to determine whether GAP-134 [(2S,4R)-1-(2-aminoacetyl)-4-benzamido-pyrrolidine-2-carboxylic acid], a small dipeptide gap junction modifier, can improve conduction and ultimately prevent AF/AFL. In rat atrial strips subjected to metabolic stress, GAP-134 prevented… 

Figures and Tables from this paper

GAP-134 ([2S,4R]-1-[2-Aminoacetyl]4-Benzamidopyrrolidine-2-Carboxylic Acid) Prevents Spontaneous Ventricular Arrhythmias and Reduces Infarct Size During Myocardial Ischemia/Reperfusion Injury in Open-Chest Dogs

GAP-134 is an effective antiarrhythmic agent with potential to reduce ischemia/reperfusion injury in dogs subjected to 60-minute and 4-hour reperfusion model.

Improving cardiac gap junction communication as a new antiarrhythmic mechanism: the action of antiarrhythmic peptides

Antiarrhythmic peptides are effective against ventricular tachyarrhythmias, such as late ischaemic ventricular fibrillation, CaCl2 or aconitine-induced arrhythmia, and it is still a matter of debate whether these drugs also act against atrialfibrillation.

Role of gap junction channel in the development of beat-to-beat action potential repolarization variability and arrhythmias.

The use of gap junction channel enhancers and inhibitors may help to reveal the precise role of gap junctions in the development of arrhythmias as well as monitor the degree of coupling of myocardium.

The role of connexin40 in atrial fibrillation.

The role of Cx40 is focused on, showing that abnormal C x40 expression is correlated with both trigger formation from the thoracic veins as well as enhanced vulnerability of the atrial myocardium to AF.

Antiarrhythmic therapy in atrial fibrillation.

  • U. Ravens
  • Biology, Medicine
    Pharmacology & therapeutics
  • 2010

GJA1-20k attenuates Ang II-induced pathological cardiac hypertrophy by regulating gap junction formation and mitochondrial function

The importance of GJA1-20k in regulating gap junction formation and mitochondrial function in Ang II-induced cardiomyocyte hypertrophy is demonstrated, thus providing a novel therapeutic strategy for patients with cardiomeocyte hyperTrophy.

The gap junction modifier ZP1609 decreases cardiomyocyte hypercontracture following ischaemia/reperfusion independent from mitochondrial connexin 43

Dysregulation of gap junction‐mediated cell coupling contributes to development of arrhythmias and myocardial damage after ischaemia/reperfusion (I/R). Connexin 43 (Cx43) is present at ventricular



Effects of Chronic Gap Junction Conduction–Enhancing Antiarrhythmic Peptide GAP-134 Administration on Experimental Atrial Fibrillation in Dogs

Oral GAP-134 reduces pacing-induced decrease in LA wavelength and appears to attenuate AF vulnerability in dogs with less atrial mechanical remodeling, and Gap junction modulation may affect AF in some circumstances.

Discovery of (2S,4R)-1-(2-aminoacetyl)-4-benzamidopyrrolidine-2-carboxylic acid hydrochloride (GAP-134)13, an orally active small molecule gap-junction modifier for the treatment of atrial fibrillation.

Small molecule gap-junction modifiers with improved physical properties were identified from a Zealand Pharma peptide library using pharmaceutical profiling, established SAR around 3, and a putative pharmacophore model for rotigaptide.

Connexin 43 Downregulation and Dephosphorylation in Nonischemic Heart Failure Is Associated With Enhanced Colocalized Protein Phosphatase Type 2A

In nonischemic HF in rabbits and humans, there is a decrease in both Cx43 expression and phosphorylation that contributes to uncoupling, which may be a potential therapeutic target to improve conduction in HF.

Effects of sterile pericarditis on connexins 40 and 43 in the atria: correlation with abnormal conduction and atrial arrhythmias.

  • K. RyuLi Li A. Waldo
  • Biology, Medicine
    American journal of physiology. Heart and circulatory physiology
  • 2007
The transmural gradient in the volume fraction of Cx40 and Cx43 in SP is associated with markedly abnormal atrial conduction and is likely an important factor in the vulnerability to induction and maintenance of AFL/AF in SP.

The Gap-Junctional Protein Connexin40 Is Elevated in Patients Susceptible to Postoperative Atrial Fibrillation

Atrial myocardium susceptible to AF is distinguished from its nonsusceptible counterpart by elevated connexin40 expression, which could give rise to different resistive properties and conduction velocities in spatially adjacent regions of tissue, which become enhanced and, hence, proarrhythmic the higher the overall level of connexIn40.

Effects of chronic atrial fibrillation on gap junction distribution in human and rat atria.

Expression of connexins 40 and 43 in human left atrium in atrial fibrillation of different aetiologies

The present study shows for the first time that AF can induce changes in the left atrium with increased connexin expression and no systematic differences between patients with paroxysmal and chronic AF were detected.